International

Human Gene Therapy
Conference

September 26 - 28, 2022 MCEC, Melbourne, Australia

Key Speakers

Paul Thomas
Paul Thomas

Director of South Australian Genome Editing (SAGE) Facility, Adelaide, Australia


Gabriela Brumatti
Gabriela Brumatti

Senior Scientist,
Cell & Gene Therapy, CSL, Victoria, Australia


John Rasko
John Rasko

Head of Dept, Royal Prince Alfred Hospital. Prof, The Univ. of Sydney. Head, Gene and Stem Cell Therapy Program, Centenary Inst., Australia

Omar Dabbous
Omar Dabbous

VP, Global Geneconomics and Outcomes Research, Gene Therapy, Novartis  Illinois, US


Arun Srivastava
Arun Srivastava

George H. Kitzman Prof. of Genetics, Chief, Division of Cellular & Molecular Therapy, Cancer & Genetics Research Complex, Florida, USA

Michelle Farrar
Michelle Farrar

Associate Professor, School of Women's and Children's Health, University of New South Wales, Australia

Ryuichi Morishita
Ryuichi Morishita

Professor of Department of Clinical Gene Therapy, Center of Medical, Innovation and Translational, Research School of Medicine, Osaka University, Japan

Hinda Daggag
Hinda Daggag

Corporate Genetic Project Head, Corporate Medical and Clinical Affairs, Abu Dhabi Health Services Co. - SEHA, UAE

Albert  Garcia Minambres
Albert Garcia Minambres

Senior Scientist, Assay Development Group, CSL, Victoria, Australia

Key Dates of Gene Forum

February 02, 2022

Abstract Submission Opens

February 25, 2022

Conference Registration Opens

June 30, 2022

Abstract Submission Deadline

April 30, 2022

Early-bird Registration Deadline

// ABOUT CONFERENCE

Welcome to Gene Therapy
Conference Australia

Gene Forum takes the honour to invite you to the International Human Gene Conference which will be held on September 26-28, 2022 at Melbourne Australia.

Over the past few years, Gene therapy has become a regular talk for the scientists and researchers from academia and industry all over the globe. Gene therapy is very huge and more team’s diverse research is needed to find the effective treatments and best possible ways to manage the rare diseases. With a great substantial research on genetics happening in this part of the world, therefore it has developed into a forum to discuss important challenges in this field.

The aim of the conference is to bring together all the key stakeholders interested in genetics and gene therapy to share and discuss advances and developments in these fields. Therefore we aimed at assisting academicians, business executives, researchers, scientists, manufacturers, gene therapy companies, communities, and agencies to keep on new developments in their specific fields and to join forces in finding alternative solutions.

It’s a unique way to approach and encourage a dialogue between speakers and delegates through its well-planned agenda with the series of talks, poster presentations, panel discussions and networking events that will keep participants engaged in learning. This will help rising scientific queries and provide solutions for a smarter and more advanced future.

We are stepping forward to create a platform to bring all the researchers from around the world and the research community to collaborate with the industries to focus on their efforts. The industry partners and attending experts will also provide a fantastic networking experience.

// SCIENTIFIC SESSION

Key Topics of Gene Forum

  • Global and regional case studies
  • Gene therapy raw materials customization
  • Efficient human genome editing
  • Vector systems and manufacturing
  • Building a global clinical trial for rare disease patients
  • Frame work and ethical practice for gene therapy in healthcare system
  • Navigating gene therapy safety in clinical development
  • Manufacturing and commercializing gene therapies in australia
  • Selection & management of suppliers and contract service provider
  • Developing translational strategy to set up for preclinical & clinical programs
  • Implication of gene therapy in health practice after clinical trial
  • Next-generation sequencing workflow In future evolution of gene therapy development

Gene Therapy Market in Australia

The Gene Therapy market is segmented by indication (Cancer, Metabolic Disorders, Eye Disorders, Cardiovascular Diseases, Spinal Muscular Atrophy and Others), technology (Adeno Virus Vector, Adeno-associated Virus Vector, Lentiviral Vector, Retroviral Vector, Herpes Virus Vector and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America).

The global gene therapy market size was valued at USD 2.26 billion dollars in 2020, and is expected to grow at a compound annual growth rate of 28.32% from 2021 to 2026 to reach USD 11,739.75 million dollars.

The advanced therapies and gene delivery technologies has created an increasingly competitive. Where a substantial number of market players are engaged in the commercialization of their gene therapy products. Therapy developers are investing in collaboration/mergers and acquisition deals as a viable strategy to enhance in-house expertise and strengthen product pipelines. These factors are expected to increase the market growth.

Some key players operating in the gene therapy market include Novartis AG, Spark Therapeutics LLC, Bluebird Bio, Gilead Sciences Inc, Celgene Corporation, Chiesi Farmaceutici S.p.A, Shire Plc, Dimension Therapeutics, Voyager Therapeutics and Celgenec Corporation.

Important factors that are driving the gene therapy market growth include recent approval of products such as Zolgensma and LentiGlobin. Spinal Muscular Atrophy (SMA) led the gene therapy market in 2020 with the highest revenue share of over 41%. However, the large B-cell lymphoma segment is estimated to account for the maximum revenue share by 2028.

Novartis and Gilead continue to expand their customer base across the globe for Kymriah and Yescarta, which are designed for the treatment of large B-cell lymphoma. Recently, in May 2019, Novartis received approval to sell its products in Japan. Moreover, as per the investigation, in 2017, around 51% of patients who received Yescarta treatment achieved.

Several payment models, such as financial-based agreements and health outcomes-based agreements, have been suggested to increase the accessibility and market survival of therapies.

Why to Attend Gene Therapy Conference?

  • Find out the new technologies that uplift progress in this field.
  • Define early industry best practices for gene therapy manufacturing, as per key lessons learned from successful therapy launches.
  • Understand the ethical considerations and challenges that surrounds gene therapy.
  • Get the latest update on vector design and development.
  • Learn how to build the most effective relationships with global and regional payers and policy makers, to ensure patient access and commercial sustainability.
  • Build strong and scalable delivery network, beyond the lab, that encourage multi-stakeholder collaboration.
  • Deep analysis into successful strategies for post-launch manufacturing scale up and delivery network integration which will reduce your time and lower costs.
  • Interactive with 10+ sessions including live Q&A and panels, make your voice heard as a thought leader.

Who will Attend Gene Therapy Conference?

Department

  • Manufacturing
  • Product Development
  • Quality
  • Value & Market Access
  • Therapy Administration
  • Research & Development
  • Regulatory Affairs
  • Vector Systems
  • Engineering
  • Laboratory
  • Science
  • Information Technology
  • Validation
  • Training
  • Clinical
  • Patient Advocacy

Job Function

  • Scientist
  • Executive and Mid-Level Management
  • Project Management
  • Technical Services
  • Supply Chain
  • Manufacturing
  • Application
  • Risk Management
  • Patient Monitoring
  • Customer Engagement
  • Marketing and Sales
  • Clinical Strategy Pharmacist
  • Product Communications
  • Clinical Research
  • Post Doc, PhD Student
// Programs

Gene Forum Program Schedule

Day - 1 [September 26 - 2022]
  • 09:00-09:30
    Opening Ceremony
  • 09:30-10:30
    Keynote Presentation
  • 10:30-11:00
    Break
  • 11:00- 12:00 Global and Regional Case Studies
  • 12:00-13:00
    - Building a Global Clinical Trial for Rare Disease Patients
  • 13:00-14:00
    Lunch Break
  • 14:00-15:00 - Panel Discussion
    - Industry Leaders Panel: Delivering Trans-formative Therapies to Patients Around the world
  • 15:00-16:00
    - Vector Systems and Manufacturing
  • 16:00-16:30
    Break
  • 16:30-17:30 - Efficient Human Genome Editing


Media Partners

geneonline
genenet
pm360


For regular updates bookmark gene therapy conferences website